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A B S T R A C T
 
Type 2 diabetes has significant adverse effects on
health-related quality of life (HRQoL). A vast array of
questionnaires has been used to measure HRQoL in di-
abetes patients, contributing to the difficulty of select-
ing instruments for future research. To systematically
evaluate these measures, a literature search was under-
taken to identify relevant publications. This paper sum-
marizes the generic, diabetes-specific, and psychologi-
cal measures utilized to evaluate persons with type 2
diabetes, and highlights related findings. Generic instru-
ments demonstrate significant reductions in health status
compared with other chronic disease populations and
healthy controls. Multiple diabetes-specific measures
are available to assess domains affected by the disease,
including symptoms, worries, self-care, locus of control,
functional ability, social support, and sexual function-
ing. Psychological measures show that type 2 diabetes is
frequently associated with adverse psychological ef-
fects, particularly depression. Since much of this re-
search has been cross-sectional in nature, little is known
about responsiveness of many of the HRQoL measures
to clinical change and treatment effects. It is clear that
HRQoL results are influenced by multiple patient and
disease factors, particularly age, gender, and the pres-
ence and severity of disease complications and comor-
bid conditions. These factors should be considered in
the design and analysis of HRQoL evaluations in type 2
diabetes patients. Selection of instruments for future re-
search will therefore require careful evaluation of study
design and objectives, population characteristics, the
presence of disease-related factors, and outcomes of in-
terest.
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Introduction
 
The adverse effects of diabetes on health-related
quality of life (HRQoL) are described in a grow-
ing body of literature. The illness, its complica-
tions and treatments, and patient attitudes all in-
teract to impair multiple dimensions of HRQoL,
including physical, role, social, cognitive, and sex-
ual functioning, emotional well-being, pain, and
health perceptions or distress. In patients with
older onset diabetes, self-rated health is a signifi-
cant predictor of mortality when physical health
status is controlled [1].
Type 2 diabetes accounts for at least 90% of dia-
betes cases in developed countries. Care of type 2
diabetes and related complications comprises a sig-
nificant proportion of health care expenditures in
the US and elsewhere and substantial indirect costs
result from premature mortality and lost produc-
tivity [2]. Formerly considered to be adult-onset
diabetes, incidence of type 2 diabetes is increasing in
younger populations including adolescents and chil-
dren [3,4]. Because of the considerable societal bur-
den of type 2 diabetes, its impact on HRQoL is a
public health issue of concern to patients, families,
employers, health care providers, and payers [3].
A variety of instruments has been used to mea-
sure HRQoL in type 2 diabetics including generic
and diabetes-specific measures, and assessments of
functional status and psychological well-being. Ge-
neric HRQoL measures provide valuable informa-
tion about the health status of patients with diabe-
tes and allow comparisons with other populations
and chronic diseases groups. Using these measures,
investigators have evaluated the association of
HRQoL with multiple factors such as glycemic con-
trol, types of treatment, numbers and types of
complications and comorbid conditions, and demo-
graphic variables. In addition, disease-specific mea-
sures have been developed to focus on dimensions
unique to diabetes. For example, diabetes-specific
concerns include the presence and “bother” of di-
abetes symptoms, attitudes, worries, self-care,
treatment satisfaction, adherence to diabetic regi-
men, locus of control, and social and family support.
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An examination of these measures and related
findings is useful when choosing an instrument
and designing future research. For this reason, a
literature review was initiated to identify and de-
scribe the generic, diabetes-specific, and psycho-
logical measures used in type 2 diabetes, and to
highlight key findings. While the effects of specific
diabetes complications on HRQoL have impor-
tant societal implications, a description of the re-
search on complications is beyond the scope of
this review.
 
Methods
 
A MEDLINE search was undertaken from 1985
through February 2000 to ascertain publications
on development of measures and systematic evalu-
ations of HRQoL in individuals with type 2 disease.
The initial date was selected because a majority of
the literature on HRQoL in diabetes has been
published since the middle 1980s. The definition
of HRQoL utilized in this paper follows the model
presented by Wilson and Cleary [5]. HRQoL do-
mains include physical, role, social, and psychologi-
cal functioning, general health perceptions, and
disease-related symptoms and concerns. In addition,
measures of diabetes-specific treatment satisfaction
were identified in this review.
The search focused on the following topics:
diabet*; NIDDM; noninsulin dependent diabetes;
type 2 diabetes; quality of life; health status; assess-
ment; and instrument. The selection of HRQoL
articles included all reviews and studies validating
questionnaires or reporting data relevant to type 2
diabetes. The author screened abstracts, selected
pertinent publications, and reviewed the articles to
identify HRQoL instruments, studies, and results.
Additional relevant publications, noted through a
secondary examination of citations, were obtained
and included in this review.
The HRQoL instruments that have been utilized
in type 2 diabetes research are highlighted below,
along with study findings relating to the effects of
the disease on HRQoL. Generic and psychological
assessments that have been applied to type 2 diabetes
are briefly described in Tables 1 and 3, respectively.
Table 2 describes the diabetes-specific measures with
supporting psychometric evaluations. Tables 1-3 are
grouped together at the end of the paper.
 
Generic Instruments (Table 1)
 
The generic HRQoL instruments used most fre-
quently to evaluate type 2 diabetes are those de-
rived from the Medical Outcomes Study (MOS),
particularly the Short Form-36 (SF-36) and Short
Form-20 (SF-20). Much of this research has been
cross-sectional in nature. MOS investigators com-
pared functional status and well being across a
number of chronic conditions [6]. Persons with di-
abetes had among the lowest scores on physical,
role, and social functioning and health perceptions,
but not on mental health or bodily pain. In a com-
parison with scores from epilepsy and multiple
sclerosis patients, MOS diabetics fared signifi-
cantly better on the SF-36 mental health scales, but
worse than the epilepsy group on health percep-
tions [7]. The MOS diabetic patients also scored
worse than epilepsy surgery patients did on emo-
tional well being [8]. Other cross-sectional studies
utilizing the MOS short forms demonstrated poor
physical functioning and health perceptions in type
2 diabetes [9] and the adverse effects of complica-
tions and comorbid conditions [9–12].
The SF-36 has been utilized in longitudinal stud-
ies of glycemic control with various results [13]. An
intensive treatment study in the Netherlands dem-
onstrated that all SF-36 scales except physical func-
tioning and general health perceptions significantly
improved after one year [14]. In this study, glycemic
control was maximized on oral therapy and patients
were switched to insulin if necessary. The insulin-
treated group had lower scores on social function-
ing and pain than the noninsulin-treated patients.
A 6-month study of diabetic patients (90% type 2)
using a day care educational program showed sig-
nificant improvements in the SF-36, independent
of glycemic control [15]. Veteran’s Administration
outpatients were followed for one year to evaluate
whether a nurse-coordinated intervention could
improve glycemic control [16]. Investigators found
no relationship between SF-36 scores and glycosy-
lated hemoglobin (HbA
 
1c
 
) after controlling for five
covariates. Similarly, the SF-36 did not predict
glycemic control in type 2 diabetics evaluated as
part of a larger cross-sectional study of Michigan
communities [17]. In Pima Indians, glycemic control
was significantly associated only with the health
change scale of the SF-36 [18]. However, a 6-month
outcomes monitoring program of diabetic out-
patients found differences in physical and social
functioning by level of metabolic control with the
highest scores relating to moderate control [19].
When doctors rated the SF-36 on behalf of their
patients, their scores for general health perceptions,
mental health, energy, role functioning (emotional),
and pain were better than those reported by their
patients [19].
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Several HRQoL studies in diabetic patients uti-
lized the SWED-QUAL, a 67-item adaptation of
the SF-36 [20–24]. A cross-sectional study found
that diabetic patients had lower scores than
matched controls for all scales except social health
[22]. In an investigation of diabetic patients (a ma-
jority treated with oral medications or diet) over a
3-year period, the only deterioration was in the
physical functioning scale [21]. Vascular and non-
vascular comorbidities were the most significant
predicting factors for SWED-QUAL outcomes dur-
ing the 3 years [23].
HRQoL in type 2 diabetes has been assessed by
a number of other generic instruments, listed in
Table 1, including the Sickness Impact Profile (SIP),
Nottingham Health Profile (NHP), EuroQol (EQ5D),
Quality of Well-Being Scale (QWB), Dartmouth
COOP/WONCA chart, Well-Being Questionnaire
(WBQ), and the World Health Organization Qual-
ity of Life Questionnaire (WHOQOL).
Like many of the SF-36 studies, the SIP was unaf-
fected by metabolic control in a Dutch cross-sec-
tional study [25]. Both the SIP and the NHP showed
impairments in diabetic patients compared with
nondiabetic controls [25]. A cross-sectional study of
social support and depression found that depressive
symptoms correlated with functional impairment as
measured by the SIP, and social support moderated
depression in patients who reported the most func-
tional disabilities [26]. Two cross-sectional studies
utilizing the NHP found that neuropathy negatively
impacted HRQoL [27,28]. Other SIP and NHP
evaluations indicated that circulatory problems, an-
gina, and other comorbid conditions were associ-
ated with reduced functioning [27–29]. In a Finnish
cross-sectional study, patients being treated with
diet alone had significantly better NHP scores than
those on orals or combination therapy, even after
results were standardized for age and gender. These
differences could be at least partly due to the shorter
duration of diabetes in the diet group since duration
was found to be a significant predictor for HRQoL
problems [29]. In a longitudinal study, the NHP
showed significant improvements for up to two
years after coronary artery bypass grafting in type 2
diabetic patients [30].
The UK Prospective Diabetes Study (UK PDS)
of over 2000 type 2 patients and 122 controls
found no significant differences in EQ5D scores
between groups receiving intensive vs. conven-
tional glucose control. However, macrovascular
complications in the last year were associated with
worse general health and more problems with mo-
bility and usual activities. The macrovascular com-
plications included nonfatal myocardial infarction,
angina, heart failure, and stroke [31].
Both the QWB and HbA
 
1c
 
 showed improvements
during an 18-month trial in patients assigned to
combined diet and exercise compared with a control
group who received education only [32].
In a Dutch study utilizing the COOP chart, type
2 diabetic patients scored significantly worse than
matched controls on physical fitness and overall
health [25].
The WBQ is one of several scales developed by
Bradley and colleagues to assess the effects of dia-
betes [33–40]. Development of this scale was
based on the Health Belief Model [35,40]. Al-
though no correlation was found between WBQ
and HbA
 
1c
 
 levels, depression and anxiety were as-
sociated with patient ratings of recent diabetic
control [37]. Women had significantly higher de-
pression and anxiety and lower general well-being
scores than men and their anxiety scores corre-
lated with more overweight [37].
Croatian investigators used the WHOQOL in a
2-month study of patients switched from oral to
insulin therapy compared with patients remaining
on orals [41]. In this small sample, patients
switched to insulin had worse scores for overall
HRQoL and independence level than those re-
maining on orals, but switched patients improved
in psychological state.
 
Diabetes-Specific Instruments (Table 2)
 
A large number of diabetes-specific instruments
have been developed. Some of these measures have
been used in both type 1 and type 2 diabetes. Two
diabetes-specific instruments were created for ap-
plication in clinical trials. The Diabetes Quality of
Life (DQOL) measure was devised for the Diabe-
tes Control and Complications Trial (DCCT) [42,43]
and the Diabetes Quality of Life Clinical Trial Ques-
tionnaire (DQLCTQ) was incorporated into treat-
ment trials with insulin lispro [44,45].
Although the DQOL was developed for evalua-
tion of type 1 diabetics, it has also been used to as-
sess type 2 patients [42,46–48]. In addition to four
scales encompassing satisfaction, impact, diabetes-
related worry, and social/vocational worry, the
DQOL also includes 16 items that assess school-
ing, experience, and family relationships of ado-
lescent populations [49]. The instrument has been
adapted to other languages [47,48,50,51] and use
in youths [52,53]. Results of the DCCT appear to
demonstrate that patients undergoing intensive
treatment for type 1 diabetes do not experience
 S-18
 
Luscombe
 
HRQoL decrements in spite of increased frequency
of hypoglycemia and more demands relating to di-
abetes care [54]. However, it is possible that the
DQOL and other instruments used in the trial are
not sufficiently sensitive to detect differences relat-
ing to improved glycemic control and delayed on-
set of disease complications.
The DQLCTQ was validated and refined in
multinational clinical trials of insulin treatment
for types 1 and 2 diabetics [44,45]. Items and
scales were drawn from the MOS and DQOL,
with the addition of newly constructed domains.
Two generic scales (energy/fatigue and health dis-
tress) and 2 diabetes-specific domains (treatment
flexibility and treatment satisfaction) were used as
primary outcomes in multinational trials of insulin
treatment. These crossover trials, conducted in the
US, Canada, France, and Germany, evaluated
three months of treatment with insulin lispro com-
pared with regular human insulin in types 1 and 2
diabetics. Both treatment satisfaction and treat-
ment flexibility were significantly improved for
type 1 patients treated with the insulin lispro, but
no significant HRQoL improvements were noted
for type 2 patients [44].
Most of the other diabetes-specific measures
have been examined in cross-sectional studies and
show at least preliminary internal consistency and
reliability. Some of the measures have been evalu-
ated for test-retest reliability or stability. Because
very few longitudinal studies have been conducted
with the instruments, responsiveness to clinically
meaningful change is largely unknown.
A cross-sectional validation study for the Dia-
betes-39 provided initial evidence of the instru-
ment’s reliability and construct validity in proba-
ble types 1 and 2 diabetes patients [55]. The
instrument has been shown to discriminate be-
tween perceived levels of diabetes severity and
types of therapy (patients on combination therapy
had worse scores than the other therapy groups).
The measure has also been translated into multiple
languages [56].
Several instruments were developed to assess
diabetes adjustment and self-care. The ATT39, de-
signed in Australia [57], and the Problem Areas in
Diabetes Survey (PAID), tested in Boston females
requiring insulin [58], measure emotional or psy-
chosocial adjustment to diabetes. Relative stability
was demonstrated with the ATT39 over a 6-month
period. The PAID was associated with HbA
 
1c
 
 even
after adjustments for age, diabetes duration, gen-
eral emotional distress, and adherence to self-care
behaviors [58]. The PAID score was also related
to psychosocial distress, disordered eating, fear of
hypoglycemia, and complications. No differences
in the scores were found between types 1 and 2 di-
abetes.
The Diabetes Care Profile (DCP) measures psy-
chosocial and educational needs of individuals
with diabetes, and includes scales for self-care and
support attitudes. The instrument was originally
developed as the Diabetes Educational Profile
[59,60]. While the instrument contains 14 scales
[61], two more were added for a study conducted
in both African American and Caucasian diabetics
[62]. Eight of the scales were compared with the
SF-36 in another community-based cross-sectional
study [17]. The DCP was found to have predictive
validity with regard to glycemic control, while the
SF-36 did not. The DCP scores differed by diabe-
tes type and treatment [61], and more severe dis-
ease was associated with greater difficulty control-
ling diabetes. Insulin-treated patients reported greater
disease impact on their social and personal lives, and
more exercise barriers and support needs than pa-
tients not using insulin [61,62]. The social and per-
sonal factor and positive attitude subscales corre-
lated with reports of at least one complication in
patients using insulin [17].
The Diabetes Health Profile (DHP) evaluates
the psychosocial profile of insulin-requiring pa-
tients, including barriers to activity, psychological
distress, and disinhibited eating. It has been adapted
to Dutch and tested in Dutch populations referred for
insulin therapy [12,14]. The Dutch version was in-
sensitive to number of complications [12]. Younger
age, hypertension, and retinopathy negatively influ-
enced disinhibited eating. A hyperglycemic com-
plaint of fatigue had a significant negative impact on
psychological distress and barriers to activity [12].
The Diabetes Impact Measurement Scale (DIMS)
assesses diabetes symptoms, morale, social-role
fulfillment, and well-being for both types 1 and 2
diabetics [63]. A cross-sectional study found high
correlations with global ratings of clinical status
by patients and clinicians, but low correlations
with clinical data.
The Diabetes Health Status Questionnaire (DHS)
was developed for a longitudinal study of lifestyle
modification to control weight in type 2 patients
[64]. The score was not significantly improved after
4 months of treatment with life-style modification.
The perceived control scales [35,38] and Diabe-
tes Treatment Satisfaction Questionnaire (DTSQ)
[37,65] are among the scales developed by Bradley,
Lewis and colleagues. The perceived control scales
measure personal, medical, and situational control.
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The scales were tested in both insulin-requiring dia-
betics and patients using oral agents. Cross-sectional
studies found that diabetic patients were more
likely to attribute responsibility for their diabetes
management to personal rather than medical or
situational control [35,38]. Furthermore, patients
scoring higher on the personal control scale had
better glycemic control, general well-being, treat-
ment satisfaction, and lower weight.
The DTSQ was adapted and extended from a
measure designed for type 1 patients and was
found to correlate strongly with the WBQ [37].
Treatment satisfaction was associated with less
overweight in men, and lower HbA
 
1c
 
 levels and
better ratings of recent diabetic control in both
sexes [37]. Both the DTSQ and the WBQ have
been adapted for use in a number of countries.
The JEVIN-trial conducted in Germany applied
these questionnaires in a comparison of intensive
vs. conventional insulin therapy in type 2 diabet-
ics. No differences in either measure were found
between the two treatment groups [66]. In a
Swedish psychometric study of the DTSQ, insulin-
treated women had lower treatment satisfaction
scores than diet/tablet-treated women [67]. A Dutch
study found no significant differences between the
computerized and standard versions of the DTSQ
scale [68].
The Diabetes Activities Questionnaire (TDAQ)
measures adherence to the diabetes regimen. This
instrument was developed and tested in types 1
and 2 diabetic patients treated with either insulin
or oral agents in Ontario, Canada [69]. Prelimi-
nary evidence of reliability was demonstrated for
the total scale and two subscales, treatment and
lifestyle monitoring.
Two measures are included in Table 2 although
they do not measure overall HRQoL. Initial vali-
dation of the Diabetes Fear of Injecting and Self-
testing Questionnaire (D-FISQ) was conducted in
adult insulin-treated diabetic patients [70]. The
authors suggest its usefulness for both clinical
practice and research. The Type 2 Diabetes Symp-
tom Checklist (DSC-Type 2) has been used in sev-
eral Dutch HRQoL studies [71,72] to examine the
relationship of symptoms with glycemic control
and measures of neuroticism, well-being, and mood
[73]. A cross-sectional study found that higher
HbA
 
1c
 
 levels correlated with worse DSC-Type 2
scores for all domains except hypoglycemic, car-
diovascular, and ophthalmological [71]. A 1-year
follow-up study was conducted with patients ran-
domized to two different target levels of glycemic
control. Participants completed the Netherlands
Personality Questionnaire, the DSC-Type 2, a short-
ened version of the Profile of Mood States, and the
Affect Balance Scale [73]. Patients who scored high
on the neuroticism scale tended to report signifi-
cantly more symptoms. A decrease of 1% or more
in HbA
 
1c
 
 had an unfavorable effect on neuro-
pathic sensibility symptoms. The other symptom
scales were not significantly affected, except for
improvements in the hyperglycemic and cardio-
vascular scales in persons 70 years of age or
greater. All symptom scores except hyperglycemic
and ophthalmological tended to be worse with ini-
tiation of insulin treatment. A prospective 2-year
cohort study examined the effect of insulin treat-
ment in 39 patients who had been treated with
diet and/or oral hypoglycemic agents [72]. The ini-
tiation of insulin therapy was significantly associ-
ated with improved glycemic control and weight
gain. DSC-Type 2 scores were not significantly in-
fluenced by the initiation of insulin treatment, but
high insulin doses were associated with worse
overall symptom and hypoglycemic scale scores.
 
Condition-Specific Battery Measures
 
A number of studies utilized batteries of instru-
ments or constructed scales to evaluate HRQoL in
diabetic patients. Using constructed measures, a
24-week treatment study found no differences be-
tween treatments when evaluating depression, anxi-
ety, energy, positive well-being, and treatment satis-
faction in type 2 patients treated with insulin vs. oral
agents [74].
One battery, developed for measuring HRQoL
in hypertensive patients with diabetes, included
items from the Mental Health Index as well as
constructed scales for general health perceptions
and sleep disturbance, disease-specific health per-
ceptions, sexual dysfunction, general health sta-
tus, side-effects, and symptoms [75]. A pilot study
demonstrated preliminary evidence for internal
consistency and test-retest reliability of the scales.
The measures discriminated among groups of nor-
mal volunteers, diabetic patients, and hypertensive
patients [75]. The hypertensive patients reported
the highest degrees of life interference due to
symptoms such as “fatigue, tiredness, feeling un-
well or other physical ailments.”
These authors also examined HRQoL changes
in a 12-week placebo-controlled trial of glipizide
gastrointestinal therapeutic system (GITS) using
five visual analogue scales that measured per-
ceived health, mental health, cognitive function,
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symptom distress, and an overall HRQoL rating
[76]. Treatment differences favoring the GITS
group were found in all of the domains except the
mental health scale, but subscales for emotional
health and depression were significantly improved
in the GITS group. Favorable HRQoL outcomes
were associated with reduced distress from hyper-
glycemia symptoms. Symptoms of hypoglycemia
did not differ between the treatment groups. Cali-
bration showed that increases in HbA
 
1c
 
 levels of
1% or greater were associated with substantial
decrements in HRQoL while HbA
 
1c
 
 reductions
were related to smaller positive changes in HRQoL.
At the end of this trial, a subgroup of patients was
asked to rate 10 health-state descriptions on a ther-
mometer scale ranging from 0 (death) to 100 (full
health). The mean rating of their current health of
83 
 

 
 8% was inversely correlated with baseline fast-
ing glucose levels [77]. Results of this survey suggest
that glycemic control may influence HRQoL [78].
The authors conclude that some generic HRQoL
measures may be too insensitive to identify changes
at these levels.
 
Psychological Functioning (Table 3)
 
Multiple psychological measures have been utilized
in diabetes research, including the Center for Epide-
miologic Studies-Depression (CES-D) Scale, Zung
Self-Rating Depressions Scale (ZSDS), Short Zung
Self-Rating Depressive Scale, Symptom Check-List
90-Revised (SCL-90-R), Profile of Mood States
(POMS), Hospital Anxiety and Depression Scale
(HADS), and Beck Depression Inventory (BDI).
The CESD and the Zung measures indicated
more depression in diabetic subjects compared with
nondiabetic controls in French and Finnish studies
[79,80]. In one of the cross-sectional Finnish stud-
ies, depression as measured by the ZSDS was associ-
ated with HbA
 
1c
 
 of greater than 9% and combined
oral and insulin treatment. Another Finnish study of
diabetics with 10 years duration of the disease
found no difference in ZSDS scores when results
were compared with nondiabetic controls [81].
Use of the SCL-90-R in outpatients with types 1
and 2 diabetes suggests that both recent and past
psychiatric disorders influence HRQoL, and the
negative effects increase with severity of psychiat-
ric symptoms [82]. Jacobson et al. found no signif-
icant interactions between diabetes type, numbers
of complications, or psychiatric status. The au-
thors concluded that psychiatric interventions for
conditions such as depression could improve the
HRQoL of diabetic patients.
Two studies utilizing the POMS were con-
ducted in patients participating in the UK PDS
[31,83]. No significant differences in scores were
identified by type of therapy (intensive vs. conven-
tional glucose control). However, more total mood
disturbance and tension were found in patients
who reported a microvascular complication in the
past year and in insulin-treated patients with at
least two hypoglycemic episodes during that time.
Dutch studies of type 2 diabetic patients were
conducted with a shortened version of the POMS.
These included a cross-sectional evaluation of gly-
cemic control [71], a 1-year randomized study of
two glycemic control target levels [73], and a 2-year
cohort study of well-being and symptoms in relation
to insulin therapy [72]. In the 1-year study, a de-
crease of 1% or more in HbA
 
1c
 
 was associated with
favorable changes on the displeasure scale (depres-
sion, anger, and tension) and a decline in the ten-
sion score in women. The cross-sectional study
found that worse fatigue scores were associated
with higher HbA
 
1c
 
 levels. The displeasure score
was 29% higher (worse) in patients who started
insulin therapy than those who did not.
The HADS was administered to a group of Lon-
don outpatients to evaluate the relationship of anx-
iety and depression with HRQoL [84]. HRQoL
was measured by an enhanced MOS-36 previously
tested in an UK sample of persons with HIV [85].
Patients with depression reported lower scores on
all the scales except pain. Anxiety was associated
with lower scores except for the physical, social,
and role functioning scales.
The BDI effectively discriminated depressed
from nondepressed diabetic subjects in a cross-sec-
tional study [86], and was used to show a positive
correlation between depressive symptoms and func-
tional impairment as measured by the SIP [26]. Pre-
viously diagnosed diabetics had higher age-adjusted
scores on the total BDI and affective and somatic
subscales than either newly diagnosed diabetics or
normal adults [87]. Number of chronic conditions
and age were independent predictors of depressive
symptoms.
 
Factors Affecting HRQoL
 
The impact of diabetes on HRQoL is influenced by
factors such as age, gender, and presence or severity
of complications and comorbid conditions [12,18].
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Physical functioning and health perceptions appear
to be particularly sensitive to these factors [9–11,17].
Advancing age of people with diabetes has been
associated with reduced physical functioning, bet-
ter mental health, increased resignation to chronic
illness, and less tolerance for ambiguities of the
disease [9,10,29,56,57]. A population-based study
found that age and number of other chronic con-
ditions were independent predictors of depressive
symptoms, particularly for previously diagnosed
patients; newly diagnosed patients did not differ
from normal individuals [87].
Gender also influences how patients report
HRQoL. Men with diabetes tend to report better
HRQoL than women, consistent with general popu-
lation studies [56]. One group of investigators found
that women had more depression and anxiety and
lower scores for general well-being than men and
their anxiety scores correlated with more overweight
[37]. Others documented higher treatment satisfac-
tion and less disease impact or burden in men [56].
The presence of complications or comorbid con-
ditions is perhaps the most significant influence on
HRQoL of diabetic patients. Both the number and
severity of complications consistently impair HRQoL
[9,10,12,17,27,31,35,40,58]. Duration of disease has
shown a variable effect, and may not be as important
a factor as the number and severity of complications.
In two Finnish studies, duration was associated with
reduced HRQoL, particularly physical functioning
[11,29]. Conversely, a Swedish study found no asso-
ciation between disease duration and WBQ or
DTSQ scores [67]. Similarly, disease duration did
not affect scores of the Diabetes-39 instrument in
cross-sectional validation studies [55].
While research indicates that depression and other
psychiatric symptoms are increased in outpatients
with diabetes compared with nondiabetic controls
[79,80,87–89], one group of authors suggests that
biases and methodological problems encountered in
prevalence studies may interfere with the strength
of these findings [90]. In addition, it is uncertain
whether complications or comorbid conditions in-
crease depressive symptoms in diabetic patients.
Some research suggests that depression in individu-
als with diabetes is independent of complications
[82]. Most other studies show that depressive symp-
toms are worse in the presence of these conditions
[87,89,91,92], particularly neuropathy [81,93].
The effect of treatment regimens on HRQoL is
uncertain. There is some evidence that HRQoL di-
minishes as treatment moves from diet and exer-
cise to oral agents to combination therapy or insu-
lin alone [56]. However, this progression may also
reflect increased severity of the disease, advancing
age, increased obesity, and more complications
and comorbid conditions. Insulin treatment has
been associated with reduced satisfaction with di-
abetes and greater impact of the disease on social
and personal lives [42,61]. A Netherlands study
found that patients switched to insulin had lower
scores on social function and pain [14]. Treatment
with a combination of insulin and oral agents has
been associated with impaired mental health [11].
 
Table 1
 
Generic quality of life questionnaires used in type 2 diabetic populations
 
Measure Description
Short Form 20
(SF-20)
6 subscales: physical, role, and social functioning; mental health; pain; health perceptions; summed items 
within scales; transformed to 0-100 scale where 100 is best
Short Form 36
(SF-36)
36 items, 8 scales: physical functioning, role functioning (physical or emotional), bodily pain, general health, 
vitality, social functioning, mental health; scale scores transformed to 0–100 scales where 100 is best; 
physical and mental health summary scores can also be calculated
Sickness Impact 
Profile (SIP)
136 statements: physical and psychosocial dimensions and independent categories; scores for overall SIP, 
12 categories, and 2 dimensions
Dartmouth COOP/
WONCA Chart
6 domains assessed by single items on a 5-point scale: physical activities, feelings, daily activities, social 
activities, change in health, and overall health; a pictograph represents the options
Nottingham Health
Profile (NHP)
38 items, 6 domains: energy, sleep, pain, physical mobility, emotional reactions, social isolation; scores are 
weighted and transformed to 0–100 scale; high score is greater severity
Quality of Well-Being
Scale (QWB) 
3 functional scales (mobility, physical activity, social activity), 36 symptom/problem complexes (later 
reduced to 25) [98]; QWB index adjusted by preference weights obtained from random samples of 
general population
EuroQol (EQ5D) 5 dimensions with 3 levels of responses: mobility, self-care, usual activity, pain/discomfort, and anxiety/
depression; single index, 5 domain scores; used in valuation of health states
Well-Being
Questionnaire (WBQ)
18 items measuring psychological well-being are scored on a 4-point Likert Scale for an overall general 
well-being scale and 3 subscales: depression, anxiety, and positive well-being
World Health Organization
Quality of Life 
Questionnaire (WHOQOL)
100 items scored on a 5-point Likert scale; overall quality of life and 6 domains: physical health; 
psychological state; level of independence; social relationships; environment; spirituality, religion and 
personal beliefs; higher results indicate better HRQoL [99]
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Table 2
 
Self-administered diabetes-specific scales used in type 2 diabetes
 
Instrument Scales Studies
Psychometric Findings
(Psychometric evaluation performed for total 
study population unless otherwise specified)
 
Diabetes Quality
of Life (DQOL)
46 items, 4 scales: satisfaction, impact, 
diabetes-related worry, social/vocational 
worry; 5-point Likert scale; higher score 
represents lower HRQoL
Developed for the 
Diabetes Control and 
Complications Trial 
(DCCT) [42,43,49,54]
Oriented for type 1 diabetes, but also used in type 2; 
internal consistency, test-retest reliability and 
convergent validity demonstrated in type 1 [43]
DQOL The DQOL transformed to 100-point scale 
with 100 representing highest HRQoL; 
not all items relevant for type 2 patients
Cross-sectional study of 
240 outpatients 
 

 
18 
years of age; 129 were 
type 2 of whom 53% 
used insulin [42]
Psychometric evaluation of DQOL and SF-36 
confirmed reliability of the measures and modest 
overlap in areas of functioning; DQOL not 
confounded by education, sex, or duration of 
diabetes but was affected by marital status
DQOL Cross-sectional survey of 
Chinese immigrants with 
type 2 diabetes [47]
Pilot study to test instruments translated into 
Chinese; internal consistency reliability 
satisfactory
DQOL Cross-sectional survey of 
70 type 2 elderly 
diabetes patients in 
Toronto [48] 
Internal consistency and test-retest reliability 
satisfactory; a trend toward increasing scores 
with more complications suggests divergent 
validity
Diabetes Quality of
Life Clinical Trial
Questionnaire
(DQLCTQ) 
Revised version contains 57 items, 8 
generic and disease-specific domains: 
physical function, energy/fatigue, health 
distress, mental health, satisfaction, 
treatment satisfaction, treatment 
flexibility, and frequency of symptoms. 
Scores converted to a 100-point scale 
with higher values indicating better 
HRQoL
Pilot study and 2 
randomized cross-over 
multinational trials of 6 
months duration; 468 
type 1 patients and 474 
type 2 patients treated 
with insulin [44,45]
Internal consistency, reliability and test-retest 
reproducibility acceptable for most domains; 
social stigma and social and diabetes worry scales 
eliminated because of low reliability; final 8 
domains discriminated between the sexes, 
diabetes type, tight and poor metabolic control, 
and good and poor self-perceived control; 
responsiveness to clinical change in metabolic 
control shown for treatment satisfaction, health/
distress, mental health, and satisfaction
Diabetes-39 39 items, 5 scales: energy and mobility, 
diabetes control, anxiety and worry, 
social burden, and sexual functioning; 
scored on a VAS (visual analog scale) 
from 1 to 7; 0-100 score with high score 
indicating maximum impact
2 cross-sectional 
development and 
validation studies in 
probable types 1 and 2 
patients [55]
Internal consistency reliability correlations above 
0.70; construct validity evaluated relative to SF-36 
with strong correlations except for diabetes 
control and sexual function scales
ATT39 Scale 39 Likert-scale items measuring emotional 
adjustment in diabetics; high scores 
indicate a negative attitude to diabetes
Validation study in Sydney 
included 166 type 2 
patients [57]
Internal consistency; test-retest reliability at 2 
weeks, 3 and 6 months demonstrated
Problem Areas in
Diabetes Survey
(PAID) 
20 items measure psychosocial adjustment 
to diabetes on a 6-point Likert scale; 
sums to a total scale score
Cross-sectional survey of 
451 types 1 and 2 female 
patients requiring insulin 
(82% type 1) [58]
Psychometric study included other measures, e.g., 
Brief Symptom Inventory and Hypoglycemia Fear 
Survey; internal consistency satisfactory for PAID
Diabetes Care 
Profile (DCP)
234 items, 14 scales: control problems; 
social and personal factors; positive and 
negative attitude; self-care ability, 
importance of care; self-care and diet 
adherence; medical, exercise, and 
monitoring barriers; long-term care 
benefit; understanding management 
practice; support attitude
Cross-sectional studies in 
two samples: 440 
diabetics from 8 
communities (89% type 
2) and 428 medical 
center patients (67% type 
2); 34% of type 2 
diabetics used insulin 
[61]
Examined reliability, construct and concurrent 
validity; reliability coefficients ranged from 0.60 to 
0.95; lower scores on the CESD Scale correlated 
with higher self-care adherence and fewer 
monitoring problems; other correlations support 
validity
DCP 16 scales were assessed: 14 scales as above 
plus support and support needs
Cross-sectional survey of 
746 patients, 98% type 2; 
511 were African 
American (53% using 
insulin) [62]
Reliability of DCP satisfactory in both African 
American and Caucasian type 2 patients, except 
the support attitude scale had a reliability 
coefficient 
 

 
0.70
DCP 8 DCP scales were evaluated: control 
problems, social and personal factors, 
positive and negative attitude, self-care 
ability, exercise barriers, long-term care 
benefits, support attitudes
Cross-sectional survey of 
255 type 2 (36% on 
insulin) [17]
Internal consistency reliability and correlations with 
SF-36 demonstrated for the 8 scales
Diabetes Health
Profile (DHP)
43 items, 3 dimensions: barriers to activity, 
psychological distress, disinhibited eating; 
4-point Likert scale
Cross-sectional study of 
2239 insulin requiring 
and insulin dependent 
patients in the UK [96]
Internal consistency satisfactory; construct-
convergent validity supported by correlations 
with SF-36 and HADS
DHP Cross-sectional validation 
study of 99 type 2 
patients referred for 
insulin therapy in The 
Netherlands [12]
DHP adapted to Dutch using forward and backward 
translations; internal consistency satisfactory; 
most correlations with SF-36 as expected
Diabetes Impact 
Measurement
Scales (DIMS)
Scores for total scale and 4 subscales: 
diabetes-specific symptoms, nonspecific 
symptoms, diabetes-related morale, 
social-role fulfillment, well-being; high 
scores are more positive
Psychometric study of 130 
types 1 and 2 patients 
(77% on insulin, 59% type 
2) [63]
One major factor identified; internal consistency and 
test-retest reliability satisfactory
(continued)
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Table 2
 
(Continued)
 
Instrument Scales Studies
Psychometric Findings
(Psychometric evaluation performed for total 
study population unless otherwise specified)
 
Diabetes Health Status 
Questionnaire (DHS)
20 diabetes-related symptoms and 6 items 
rating current health and energy on a 
5-point Likert scale
Longitudinal study of 
lifestyle modification for 
weight control in 66 type 
2 patients [64]
Internal consistency reliability satisfactory
Perceived Control 
scales
7 subscales and 3 composite scores: 
personal control, medical control, and 
situational control
Cross-sectional studies of 
286 insulin-requiring 
patients [35] and 187 
patients treated with oral 
agents [38]
Internal consistency satisfactory for composite 
scales in patients treated with oral agents
Diabetes Treatment 
Satisfaction 
Questionnaire 
(DTSQ)
6 items about various aspects of treatment 
satisfaction rated on a 7-point scale, plus 
2 individual items concerning hypo- and 
hyperglycemia
Cross-sectional study of 
diabetics treated with 
oral agents [37]
181 patients completed the DTSQ; reliability 
coefficients satisfactory; item-total correlations 
ranged from 0.53 to 0.62
DTSQ A postal survey of 734 
diabetics 60 years (17% 
on diet alone, 55% on 
orals, 28% on insulin) 
[97]
Treatment satisfaction positively associated with 
oral therapy and correlated with the general well-
being score of the WBQ
DTSQ Randomized cross-over 
study of 105 diabetes 
patients (45 type 2) [68]
Compared standard and computerized Dutch 
versions of the DTSQ and WBQ; internal 
consistency and test-retest reliability satisfactory 
for both measures
DTSQ Cross-sectional study of 
423 patients (153 on 
insulin; 270 diet and/or 
orals) [67]
Psychometric validation of Swedish versions of the 
DTSQ and the WBQ; internal reliability 
satisfactory
The Diabetes Activities 
Questionnaire 
(TDAQ)
13 items scored on a VAS 100 mm in length 
for total scale and 2 subscales: treatment 
and lifestyle/monitoring 
Development and cross-
sectional pilot testing in 
153 individuals with type 
1 or 2 diabetes in 
Ontario, Canada (53% on 
oral agents) [69]
Factor analysis performed; test-retest reliability 
suggested stability of the questionnaire and 
satisfactory internal consistency
Diabetes Fear of 
Injecting and 
Self-testing 
Questionnaire 
(D-FISQ)
30-items, 2 scales: fear of self-injecting (FSI) 
and fear of self-testing (FST)
Cross-sectional study of 
266 insulin-treated adult 
diabetics (types 1 and 2) 
[70]
Internal consistency satisfactory; preliminary 
evidence of construct and discriminative validity; 
minimal subscale scores found for 62% (FSI) and 
57% (FST) of the population
DSC-Type 2 8 scales/6 dimensions measure frequency 
and discomfort of 34 symptoms on
4-point Likert Scale; frequency and 
weighted scores for each dimension and 
total symptom scores are calculated [73]
DSC-Type 2 used in 3 
studies in Netherlands: 
cross-sectional and 
2-year cohort studies, 
and randomized trial with 
1-year follow-up 
Correlations with Dutch POMS, Affect Balance 
Scale, questions of well-being and treatment 
satisfaction, Netherlands Personality 
Questionnaire, and HbA
 
1c
 
. Reliability not 
reported
 
Table 3
 
Psychological measures used in type 2 diabetes populations
 
Measure Description
Affect Balance Scale (ABS) 5 positive and 5 negative items; positive, negative and aggregate balance scores
Center for Epidemiologic Studies-
Depression (CES-D) Scale
20 items that measure depressive symptoms
Zung Self-Rating Depression Scale 
(ZSDS)
20 items yield a score ranging from 20 to 80; a ZSDS index calculated by multiplying score value
by 1.25
Short Zung Self-Rating 
Depressive Scale
10 items on a 4-point Likert scale yield an overall score
Symptom Check-List 90-Revised 
(SCL-90-R)
9 subscales: somatization, obsessive-compulsive symptoms, interpersonal sensitivity, depression, 
anxiety, hostility, phobic anxiety, paranoid ideation, psychoticism, and a global symptom index that 
measures the severity of psychological symptoms
Hospital Anxiety and Depression 
Scale (HADS)
Identifies states of depression and anxiety in hospital outpatients; subscales also measure severity of 
the emotional state [100]
Beck Depression Inventory (BDI) Measures existence and severity of depression; 84 statements; 21 categories; somatic and affective 
subscales; items rated on 4-point severity scale; total score ranges from 0 to 63; high score 
indicates worse depression [101,102]
Profile of Mood State (POMS) Describes extent of 58 feelings on a 5-point scale; scores for 6 mood states: tension/anxiety, 
depression/dejection, anger/hostility, vigor/activity, fatigue/inertia, confusion/bewilderment, and 
total mood-disturbance
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Discussion
 
The HRQoL consequences of type 2 diabetes are
considerable. Research indicates decrements in
virtually all aspects of HRQoL due to the disease
or its complications. Generic instruments demon-
strate significant reductions in health status com-
pared with other chronic disease populations and
healthy controls. Studies with diabetes-specific in-
struments report negative effects on multiple do-
mains including symptoms, worries, self-care, lo-
cus of control, functional ability, social support,
and treatment satisfaction.
It is important to consider population and dis-
ease characteristics in the design and analysis of
HRQoL studies since they may be significant co-
variates. The selection of HRQoL instruments is
also influenced by these factors, along with study
objectives, outcomes of interest, and relevant data
on reliability, validity, and responsiveness.
A generic HRQoL measure may be the optimal
choice of instrument when the primary goal is dis-
crimination between types of chronic disease, patient
subgroups, or levels of disease severity. While the SF-
36 has been the most frequently used generic instru-
ment to study type 2 diabetes, several other measures
have been utilized with some success. Applications
of generic instruments in longitudinal studies have
resulted in variable relationships between HRQoL
and glycemic control. It is possible that these mea-
sures lack sensitivity to changes in metabolic status.
Disease-specific instruments that include con-
cepts closely aligned with concerns of diabetes pa-
tients may be more likely than generic measures to
show responsiveness in treatment trials. An associa-
tion between HRQoL and glycemic control has
been documented with several of the instruments.
All eight of the DQLCTQ domains discriminated
between tight and poor metabolic control, and good
and poor self-perceived control. Responsiveness to
clinical change in metabolic control was shown for
four domains [45]. PAID was associated with glyce-
mic control after adjustment for age, duration, emo-
tional distress and adherence to self-care, and scores
for types 1 and 2 diabetics were comparable [58].
DCP scores differed by diabetes type and treatment.
In types 1 and 2 patients combined, correlations
with HbA
 
1c
 
 were noted for three DCP scales—con-
trol problems, self-care ability, and self-care adher-
ence. For type 2 patients not using insulin, three ad-
ditional scales correlated with HbA
 
1c
 
, i.e., social and
personal factors, negative attitude, and medical bar-
riers [61]. Patients with glycemic control scored
higher on the Personal Control Scale [35,38]. Treat-
ment satisfaction as measured by the DTSQ was as-
sociated with lower HbA
 
1c
 
 levels and better ratings
of recent diabetic control [37].
Two disease-specific instruments, the DQOL
measure [49] and the DQLCTQ [45], were devel-
oped specifically for trials of insulin-treated patients.
The DQOL is the most widely used and accepted,
but no significant differences between intensive and
conventional treatment for type 1 diabetics were
noted after 6.5 years of treatment. Two of the eight
DQLCTQ scales significantly favored insulin lispro
in crossover trials.
The DHS questionnaire was also created for a
longitudinal study, but no significant changes
were noted in the score after four months of life-
style modification for weight control [64]. A Dutch
version of the DHP, designed specifically for insulin
dependent or requiring patients, was administered
to patients in a 1-year intensive treatment study and
some improvements were noted at one year [94].
Most other disease-specific instruments have been
utilized in cross-sectional or validation studies only.
Condition-specific battery assessments have shown
mixed results in clinical trials of type 2 diabetes
patients. An advantage of a condition-specific bat-
tery is the ability to target assessments to patient
characteristics, study designs, and anticipated out-
comes. Unfortunately, reliability and validity of
the battery in a type 2 diabetic population may be
unknown. Additionally, it may be difficult to rep-
licate results with other groups of patients, differ-
ent study designs, or objectives.
Several experts have recommended that HRQoL
evaluations include both generic and disease-spe-
cific measures to capture general health status as
well as more disease-related concerns. Since psycho-
logical factors are important in diabetes, the addi-
tion of one of the psychological measures may pro-
vide valuable information not incorporated in the
other instruments. Finally, symptom assessments al-
low the opportunity to examine relationships of
HRQoL scores with patient perceptions of symp-
tom frequency and severity as well as the impact of
metabolic control on patient symptoms [76,95,96].
There is undoubtedly a need for continued re-
search in this area. The examination of HRQoL in
relation to various therapies will provide impor-
tant information for patients and clinicians. Fur-
ther study is also required to evaluate and prevent
the long-term negative HRQoL effects associated
with progression of this disease.
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